IPC
PDLI

Independent Portfolio Consultants’s PDL BioPharma, Inc. PDLI Stock Holding History

Independent Portfolio Consultants’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,935
Closed -$10K – 831
2015
Q4 		$10K Hold
2,935
– – ﹤0.01% 715
2015
Q3 		$15K Sell
2,935
-350
-11% -$2.01K ﹤0.01% 698
2015
Q2 		$21K Sell
3,285
-1,740
-35% -$11.7K ﹤0.01% 709
2015
Q1 		$35K Sell
5,025
-1,040
-17% -$7.53K 0.01% 643
2014
Q4 		$47K Hold
6,065
– – 0.01% 636
2014
Q3 		$45K Buy
+6,065
New +$56.3K 0.01% 647

Other funds holding PDLI

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Independent Portfolio Consultants's PDLI Position: Q1 2016 in Review

Independent Portfolio Consultants sold out of PDL BioPharma, Inc. (PDLI) in Q1 2016, closing a stake of 2,935 shares — an estimated $10K sold.

Independent Portfolio Consultants first reported a position in PDLI in Q3 2014 and held it in 6 quarters. The position peaked at $47K in Q4 2014. 195 funds tracked by Wall St. Rank hold PDLI as of Q1 2016.

  • Independent Portfolio Consultants reported no remaining PDL BioPharma, Inc. position as of Q1 2016 after selling out during the quarter.
  • Independent Portfolio Consultants sold 2,935 PDL BioPharma, Inc. shares in Q1 2016, an estimated $10K.
  • Independent Portfolio Consultants first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 6 quarters.
  • Independent Portfolio Consultants's PDL BioPharma, Inc. position peaked at $47K in Q4 2014.
  • 195 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2016.

Based on Independent Portfolio Consultants's 13F filing for Q1 2016, filed 13 Apr 2016.